AP
CORT icon

Atwood & Palmer’s Corcept Therapeutics CORT Stock Holding History

Atwood & Palmer’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-464
Closed -$18.7K – 504
2026
Q1 		$18.7K Hold
464
– – ﹤0.01% 329
2025
Q4 		$16.1K Hold
464
– – ﹤0.01% 344
2025
Q3 		$38.6K Hold
464
– – ﹤0.01% 267
2025
Q2 		$34.1K Hold
464
– – ﹤0.01% 267
2025
Q1 		$53K Hold
464
– – ﹤0.01% 220
2024
Q4 		$23.4K Hold
464
– – ﹤0.01% 275
2024
Q3 		$21.5K Sell
464
-609
-57% -$21.6K ﹤0.01% 285
2024
Q2 		$34.9K Buy
+1,073
New +$29.4K ﹤0.01% 249

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Atwood & Palmer's CORT Position: Q2 2026 in Review

Atwood & Palmer sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 464 shares — an estimated $18.7K sold.

Atwood & Palmer first reported a position in CORT in Q2 2024 and held it in 8 quarters. The position peaked at $53K in Q1 2025. 188 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Atwood & Palmer reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Atwood & Palmer sold 464 Corcept Therapeutics shares in Q2 2026, an estimated $18.7K.
  • Atwood & Palmer first reported a position in Corcept Therapeutics in Q2 2024 and held it in 8 quarters.
  • Atwood & Palmer's Corcept Therapeutics position peaked at $53K in Q1 2025.
  • 188 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Atwood & Palmer's 13F filing for Q2 2026, filed 8 Jul 2026.